These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Conventional Ultrasound, Immunohistochemical Factors and BRAF Chen J; Li XL; Zhao CK; Wang D; Wang Q; Li MX; Wei Q; Ji G; Xu HX Ultrasound Med Biol; 2018 Nov; 44(11):2296-2306. PubMed ID: 30100099 [TBL] [Abstract][Full Text] [Related]
4. Risk factors for central lymph node metastasis in patients with papillary thyroid carcinoma: a retrospective study. Du J; Yang Q; Sun Y; Shi P; Xu H; Chen X; Dong T; Shi W; Wang Y; Song Z; Shang X; Tian X Front Endocrinol (Lausanne); 2023; 14():1288527. PubMed ID: 38047112 [TBL] [Abstract][Full Text] [Related]
5. The synergic effect of BRAF Qu HJ; Qu XY; Hu Z; Lin Y; Wang JR; Zheng CF; Tan Z Endocr J; 2018 Jan; 65(1):113-120. PubMed ID: 29070763 [TBL] [Abstract][Full Text] [Related]
6. Association of BRAF V600E Mutation and MicroRNA Expression with Central Lymph Node Metastases in Papillary Thyroid Cancer: A Prospective Study from Four Endocrine Surgery Centers. Han PA; Kim HS; Cho S; Fazeli R; Najafian A; Khawaja H; McAlexander M; Dy B; Sorensen M; Aronova A; Sebo TJ; Giordano TJ; Fahey TJ; Thompson GB; Gauger PG; Somervell H; Bishop JA; Eshleman JR; Schneider EB; Witwer KW; Umbricht CB; Zeiger MA Thyroid; 2016 Apr; 26(4):532-42. PubMed ID: 26950846 [TBL] [Abstract][Full Text] [Related]
7. Predicting factors of central lymph node metastasis and BRAF Zhou SL; Guo YP; Zhang L; Deng T; Xu ZG; Ding C; Sun WC; Zhao YW; Kong LF World J Surg Oncol; 2021 Jul; 19(1):211. PubMed ID: 34256769 [TBL] [Abstract][Full Text] [Related]
8. A comprehensive prediction model for central lymph node metastasis in papillary thyroid carcinoma with Hashimoto's thyroiditis: BRAF may not be a valuable predictor. Chen Y; Zhao S; Zhang Z; Chen Z; Jiang B; An M; Shang M; Wu X; Zhang X; Chen B Front Endocrinol (Lausanne); 2024; 15():1429382. PubMed ID: 39363900 [TBL] [Abstract][Full Text] [Related]
9. Combined effect of Hashimoto's thyroiditis and BRAF(V600E) mutation status on aggressiveness in papillary thyroid cancer. Kim SJ; Myong JP; Jee HG; Chai YJ; Choi JY; Min HS; Lee KE; Youn YK Head Neck; 2016 Jan; 38(1):95-101. PubMed ID: 25213729 [TBL] [Abstract][Full Text] [Related]
10. Potential relationship between Hashimoto's thyroiditis and BRAF(V600E) mutation status in papillary thyroid cancer. Zeng RC; Jin LP; Chen ED; Dong SY; Cai YF; Huang GL; Li Q; Jin C; Zhang XH; Wang OC Head Neck; 2016 Apr; 38 Suppl 1():E1019-25. PubMed ID: 26041461 [TBL] [Abstract][Full Text] [Related]
11. BRAF V600E mutation independently predicts central compartment lymph node metastasis in patients with papillary thyroid cancer. Howell GM; Nikiforova MN; Carty SE; Armstrong MJ; Hodak SP; Stang MT; McCoy KL; Nikiforov YE; Yip L Ann Surg Oncol; 2013 Jan; 20(1):47-52. PubMed ID: 22941165 [TBL] [Abstract][Full Text] [Related]
12. Risk Factors for Neck Nodal Metastasis in Papillary Thyroid Cancer With BRAF V600E Mutation. Han Y; Hou L; Zhao B; Gao L; Li S Front Endocrinol (Lausanne); 2022; 13():884428. PubMed ID: 35784548 [TBL] [Abstract][Full Text] [Related]
13. Association between diffuse lymphocytic infiltration and papillary thyroid cancer aggressiveness according to the presence of thyroid peroxidase antibody and BRAF Lee YK; Park KH; Park SH; Kim KJ; Shin DY; Nam KH; Chung WY; Lee EJ Head Neck; 2018 Oct; 40(10):2271-2279. PubMed ID: 29935011 [TBL] [Abstract][Full Text] [Related]
14. Predictors and a Prediction Model for Central Cervical Lymph Node Metastasis in Papillary Thyroid Carcinoma (cN0). Gao X; Luo W; He L; Cheng J; Yang L Front Endocrinol (Lausanne); 2021; 12():789310. PubMed ID: 35154002 [TBL] [Abstract][Full Text] [Related]
15. [Association between BRAF V600E mutation and central lymph node metastasis in patients with papillary thyroid carcinoma]. Shi C; Qin H; Ding C; Sun Y; Lyu Y; Shi T Zhonghua Zhong Liu Za Zhi; 2015 Feb; 37(2):123-7. PubMed ID: 25975689 [TBL] [Abstract][Full Text] [Related]
16. An Online Model for Central Lymph Node Metastases in Papillary Thyroid Carcinoma With BRAF V600E Mutation. Chen H; Pan WK; Ren SY; Zhou YL Am J Clin Oncol; 2024 Aug; 47(8):383-390. PubMed ID: 38664891 [TBL] [Abstract][Full Text] [Related]
17. The Impact of Coexistent Hashimoto's Thyroiditis on Central Compartment Lymph Node Metastasis in Papillary Thyroid Carcinoma. Liu Y; Lv H; Zhang S; Shi B; Sun Y Front Endocrinol (Lausanne); 2021; 12():772071. PubMed ID: 34867817 [TBL] [Abstract][Full Text] [Related]
18. Prediction of occult central lymph node metastasis in papillary thyroid carcinoma by preoperative BRAF analysis using fine-needle aspiration biopsy: a prospective study. Joo JY; Park JY; Yoon YH; Choi B; Kim JM; Jo YS; Shong M; Koo BS J Clin Endocrinol Metab; 2012 Nov; 97(11):3996-4003. PubMed ID: 22930785 [TBL] [Abstract][Full Text] [Related]
19. Associations of the BRAF(V600E) mutation with sonographic features and clinicopathologic characteristics in a large population with conventional papillary thyroid carcinoma. Park AY; Son EJ; Kim JA; Youk JH; Park YJ; Park CS; Chang HS PLoS One; 2014; 9(10):e110868. PubMed ID: 25337709 [TBL] [Abstract][Full Text] [Related]
20. Clinical Analysis of BRAF Dong SY; Chen J; Xia EJ; Lin RX; Du HY; Wang OC; Zhang XH; Hao RT Am Surg; 2020 May; 86(5):450-457. PubMed ID: 32684022 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]